Victoza® is not indicated for weight loss.
Victoza® efficacy and safety for patients with type 2 diabetes

Consider a once-weekly GLP‑1 RA therapy
Ozempic® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction or nonfatal stroke) in adults with type 2 diabetes mellitus and established CVD.
Studies in adults with type 2 diabetes
In a head-to-head study in adults with type 2 diabetes
Victoza® consistently outperformed Januvia®1
Primary endpoint: Mean change in A1C from baseline
Studied in adults with type 2 diabetes taking metformin.
aP<0.0001 vs Januvia®.
In a head-to-head study in adults with type 2 diabetes
Victoza® provided significant weight reduction vs Januvia®1
Secondary endpoint: Mean change in weight from baseline
Studied in adults with type 2 diabetes taking metformin.
Pratley (1860)1
Study-related adverse events
In a 26-week, open-label study in adult patients (N=665) comparing Victoza® 1.2 mg, Victoza® 1.8 mg, and sitagliptin 100 mg, all in combination with metformin, the adverse reactions reported in ≥5% of patients treated with Victoza® were nausea (23.9% vs 4.6%), headache (10.3% vs 10.0%), diarrhea (9.3% vs 4.6%), and vomiting (8.7% vs 4.1%).
Study design
A 26-week, open-label, active-comparator, 3-armed, parallel-group trial to compare the efficacy and safety of Victoza® with sitagliptin for the treatment of type 2 diabetes in adults. Patients with type 2 diabetes inadequately controlled on metformin (N=665) were randomized to receive once-daily Victoza® 1.2 mg (n=225), Victoza® 1.8 mg (n=221), or sitagliptin 100 mg (n=219). The primary outcome was change in A1C.
In a head-to-head study in adults with type 2 diabetes
Victoza® was unsurpassed in A1C reduction vs Trulicity®2
Primary endpoint: Mean change in A1C from baseline
Studied in adults with type 2 diabetes taking OADs. Upper limit of the 95% CI (-0.19; 0.07) was less than prespecified noninferiority margin of 0.4%.
bStudy sponsored by Eli Lilly and Company.
In a head-to-head study in adults with type 2 diabetes
Victoza® provided significant weight reduction vs Trulicity®2
Secondary endpoint: Mean change in weight from baseline
After 26 weeks
Victoza® vs Trulicity®b

Baseline weight:
206 to 208 lb


23% greater weight loss
Studied in adults with type 2 diabetes taking OADs.
bStudy sponsored by Eli Lilly and Company.
Victoza® is not indicated for weight loss.
AWARD-62
Study-related adverse events
The most common adverse events occurring in 5% or more of adult patients in the treatment groups combined (Victoza® 1.8 mg vs dulaglutide 1.5 mg): nausea (18% vs 20%); diarrhea (12% vs 12%); vomiting (8% vs 7%); dyspepsia (6% vs 8%); constipation (6% vs 4%); nasopharyngitis (7% vs 8%); headache (8% vs 7%); back pain (5% vs 4%); decreased appetite (7% vs 5%); and minor hypoglycemia (6% vs 9%). No major hypoglycemia occurred.
Study design
A 26-week, randomized, open-label, parallel-group, multicenter (62 sites), multinational (9 countries), phase 3, noninferiority study. Patients were included based on the following criteria: adults with type 2 diabetes, treated with metformin, A1C of 7% to 10%, and a BMI of up to 45 kg/m2. Patients (N=599) were randomized to receive once-weekly Trulicity® 1.5 mg (n=299) or once-daily Victoza® 1.8 mg (n=300). The primary endpoint was change in A1C. Study sponsored by Eli Lilly and Company.
In a head-to-head study in adults with type 2 diabetes
Victoza® demonstrated powerful A1C reductions after patients switched from Januvia®3
Primary endpoint: Mean change in A1C from baseline
Studied in adults with type 2 diabetes taking metformin.
aP<0.0001 vs Januvia®.
In a head-to-head study in adults with type 2 diabetes
Victoza® provided significant weight reduction after switching from Januvia®3
Secondary endpoint: Mean change in weight from baseline
After 26 weeks
Switch to Victoza® after Januvia®

Baseline weight:
196 to 201 lb


2X greater weight loss
Studied in adults with type 2 diabetes taking metformin.
Victoza® is not indicated for weight loss.
Bailey (LIRA-SWITCH)3
Study-related adverse events
The adverse events most commonly reported in ≥5% of adult patients treated with Victoza® 1.8 mg vs Januvia® 100 mg, both in combination with metformin, were nausea (21.8% vs 7.8%), diarrhea (16.3% vs 9.3%), decreased appetite (8.9% vs 3.4%), vomiting (7.4% vs 4.9%), headache (6.4% vs 5.9%), nasopharyngitis (5.9% vs 3.4%), and increased lipase (5.5% vs 4.4%).
Study design
A 26-week, randomized, parallel group, double-blind, double-dummy, active-controlled study to compare efficacy and safety in patients switching from Januvia® 100 mg to Victoza® 1.8 mg with patients who stayed on Januvia®. Adult patients with type 2 diabetes inadequately controlled on metformin (≥1500 mg/day) and Januvia® (100 mg/day) for at least 90 days prior to screening (N=407) were randomized 1:1 to switch to once-daily Victoza® 1.8 mg in addition to a Januvia® placebo or continued Januvia® 100 mg in addition to a Victoza® placebo, both in combination with metformin. The primary endpoint was a change in A1C.
CKD=chronic kidney disease; DPP-4=dipeptidyl peptidase-4; eGFR=estimated glomerular filtration rate; GLP-1 RA=glucagon-like peptide-1 receptor agonist; OAD=oral antidiabetic drug.